RxDoctor Payments Data

Leila Shirin, MD

Neurology · Fort Worth, TXNPI 1770933434

Payments from drug & device makers

$39,925in general payments, 2019–2025

Across 550 payments — averaging $72.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$13K
  • Medtronic$11K
  • Kyowa Kirin, Inc.$6K
  • AbbVie$2K
  • Biogen$832
  • UCB, Inc.$752
  • plus $6K from 43 others

What the payments were for

  • Speaking & faculty fees$5,93815%
  • Grants$20,00050%
  • Travel & lodging$1,7304%
  • Food & beverage$12,25831%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,925 in reported general payments places this provider in the 80th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$325,497
Medicare patients
457
Services billed
11,010

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa678$1,044,359
NuplazidPimavanserin Tartrate109$712,619
IngrezzaValbenazine Tosylate54$488,973
NourianzIstradefylline122$392,480
AustedoDeutetrabenazine24$303,903
Austedo XrDeutetrabenazine17$208,402
GocovriAmantadine Hcl63$163,328
BotoxOnabotulinumtoxina27$35,450
Galantamine ErGalantamine Hbr136$16,818
Carbidopa-LevodopaCarbidopa/Levodopa367$15,962
Rasagiline Mesylate41$8,857
Primidone74$5,085
Memantine Hcl66$2,643
Donepezil Hcl151$2,339
Lacosamide15$2,215

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary$242$1,044,359678 claims
Acadia Pharmaceuticals IncNuplazid$639$712,619109 claims
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$117$512,30541 claims
Neurocrine Biosciences, Inc.Ingrezza$175$488,97354 claims
Kyowa Kirin, Inc.Nourianz$6,317$392,480122 claims
MDD US Operations, LLCGocovri$367$163,32863 claims
AbbVieBotox$2,408$35,45027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,246 neurology providers in Texas.

Other neurology in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →